Compare YELP & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YELP | RLAY |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2011 | 2020 |
| Metric | YELP | RLAY |
|---|---|---|
| Price | $23.83 | $10.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $29.17 | $14.50 |
| AVG Volume (30 Days) | 1.8M | ★ 2.3M |
| Earning Date | 05-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.15 | ★ 31.78 |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $1,464,955,000.00 | $15,355,000.00 |
| Revenue This Year | $2.53 | N/A |
| Revenue Next Year | $2.60 | $396.00 |
| P/E Ratio | $10.73 | ★ N/A |
| Revenue Growth | 3.75 | ★ 53.44 |
| 52 Week Low | $19.60 | $1.78 |
| 52 Week High | $40.25 | $11.43 |
| Indicator | YELP | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 60.91 |
| Support Level | $19.60 | $9.06 |
| Resistance Level | $34.05 | $11.43 |
| Average True Range (ATR) | 0.77 | 0.77 |
| MACD | 0.43 | 0.06 |
| Stochastic Oscillator | 78.00 | 56.56 |
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).